The FDA granted priority review, with a decision expected by 19 June 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

Caption: Structure of a HIV capsid (Left) Central slice view of a HIV virus-like particle with pore-forming toxin on the membrane (Middle) Atomic model of a HIV capsid (Right) Density map of HIV ...

LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...

“By playing with the capsid, we made an HIV-1 that does not replicate but can stimulate an immune response,” said ... single nucleus sequencing, and DNA, RNA, and protein extraction. Meet the Modular ...

Lenacapavir 463.5mg/1.5mL (309mg/mL); soln for SC inj; preservative-free. Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between ...

At the time, most existing HIV drugs worked by interfering ... a different solution - one that disrupted the viral capsid, the cone-shaped protein structure that holds the genes essential for ...

People who participated in the study also had HIV-1 RNA levels of at least 3000 copies/mL. The trial of VH499, an investigational capsid inhibitor, showed that all oral doses (25mg, 100mg ...